Biotechnology

Biotech firm Humacyte raises $20M to accelerate sales of its FDA-approved Symvess® and fund crucial trials for new hemodialysis applications.

With pivotal trials advancing, key FDA alignment, and a strong cash position, Taysha Gene Therapies charts a clear path toward a potential breakthrough.

With the FDA mandating a move from animal testing, BioIVT is positioning itself at the center of the NAMs revolution with key industry events and research.

ImmunoBrain's novel immunotherapy for Alzheimer's avoids key safety issues of other drugs and shows positive biomarker data in a Phase 1b trial.

Annovis Bio's new trial for buntanetap uses an AI-powered Apple Watch app to track symptoms, aiming for more precise data in the race for a cure.

With a new CFO who helped steer a multi-billion dollar acquisition, Bambusa Therapeutics signals major growth plans for its innovative antibody platform.

A new biotech spins out with a novel drug class aiming to provide healthier, more durable weight loss and combat cancer-related wasting syndrome.

Ractigen's RAG-01 advances with NMPA approval, using RNA activation to fight bladder cancer by targeting a previously 'undruggable' gene.

A new drug shows unprecedented activity against all common cold viruses, a major breakthrough for millions suffering from chronic lung diseases.

Quebec’s new budget maintains support for its vital life sciences sector, but industry leaders warn new tax rules could hinder innovation for small firms.

As its new obesity drug enters a key trial, Biohaven bets on a novel approach: reducing fat while preserving precious muscle mass. Can it redefine weight loss?

Belief BioMed's single-dose treatment for hemophilia B, BBM-H901, is now approved in Macao, offering a new horizon for patients beyond frequent injections.

A new DoD-funded trial combines a biologic drug with a plant-based supplement, aiming to break treatment barriers for ulcerative colitis, a major military issue.

The 'Beauty in Black' star, whose character has prostate cancer, is now a Global Ambassador for ZERO, tackling the disease's deadly toll on Black men.

Red Light Holland is deploying advanced AI from Kala Bio to accelerate its botanical psilocybin program, signaling a new high-tech era for mental health.

Amid massive layoffs and AI-driven shifts, the life sciences industry faces a structural crisis. Blue Matter's new practice offers a roadmap to survive.

The company launches new research assays for pTau217, entering a competitive field aimed at replacing invasive tests with a simple blood draw.

With fresh funding secured, Dogwood Therapeutics pushes its promising nerve pain drug, Halneuron®, toward a pivotal data readout later this year.

With a major Series B financing, Crossbow advances its TCR-mimetic therapies, aiming to unlock a new frontier in the fight against a broad range of cancers.

Biotech firm ProMIS Neurosciences reveals novel vaccine data for ALS and Parkinson's, using a platform that selectively targets only toxic proteins.